Pharma Stock Surges 170% in 4 Months as FIIs Increase Stake; Company Unveils ₹1,400 Cr Capex

Synopsis: A small-cap API and specialty chemicals maker has rallied sharply in recent months, drawing fresh interest from foreign institutional investors. Record quarterly earnings, near-full capacity utilisation and a large multi-year expansion plan have combined to put the counter firmly on investors’ radar.

Foreign institutional investors appear to be steadily building a position in this pharma and chemicals company, even as the stock has already delivered a striking rally over the past few months. Behind the price action lies a record quarter, near-peak capacity utilization, a large multi-year expansion plan, and management commentary that remains upbeat despite the sharp run-up in the share price.

With a market capitalization of Rs. 4,368 crore, the shares of IOL Chemicals & Pharmaceuticals Limited were trading at Rs. 149 per share, with a 52-week range of Rs. 179.60 to Rs. 67.19, and they are trading at a P/E of approximately 30x.

What does the company do?

IOL Chemicals and Pharmaceuticals Limited is a Punjab-based company operating across pharmaceuticals and specialty chemicals. It manufactures Active Pharmaceutical Ingredients (APIs)  the core compounds behind medicines, and is the world’s largest fully backward-integrated producer of Ibuprofen, a common pain and fever reliever, alongside a growing non-Ibuprofen portfolio including Paracetamol (fever and pain relief), Metformin (diabetes), Clopidogrel (a blood thinner), and Pantoprazole (acidity). 

On the chemicals side, it makes Ethyl Acetate, Acetic Anhydride, Iso Butyl Benzene and Triacetin  some used internally to manufacture its own medicines, and the rest sold to industries like paints, textiles, and packaging, where they serve as solvents and other basic industrial ingredients. This integration across both businesses gives it better control over costs and supply, serving customers across roughly 80 countries. 

FII and Promoters Accumulating Substantially:

IOL Chemicals and Pharmaceuticals has seen its foreign institutional investor holdings rise from 1.72% in March 2026 to 4.87% in June 2026, a jump of roughly 3.15 percentage points. Promoter holding also moved up over the same period, from 57.48% in March 2026 to 62.28% in June 2026, marking a jump of roughly 4.8%, suggesting promoters, too, have been adding to their stake rather than diluting it. 

A Sharp Rally Backed by Volumes

The stock has rallied close to 170% over roughly four months, a move that has coincided with a pickup in trading volumes, pointing to broader market participation rather than a thin, illiquid spike. Such a steep rerating typically reflects a combination of improving earnings visibility and a shift in how the market is pricing the company’s growth prospects, rather than momentum alone.

₹1,200–1,400 Crore Capex on the Cards

The company has laid out plans for a large multi-year investment programme on a newly acquired 101-acre parcel of land along the Chandigarh-Bathinda Highway. Management has indicated the total outlay could be in the range of ₹1,200–1,400 crore, to be deployed gradually over the next four to five years, with annual spending expected at around ₹200–250 crore, split roughly 60% towards growth and 40% towards infrastructure, automation and land development. Importantly, the company has stated this expansion will be funded entirely through internal accruals, without fresh debt or equity dilution. 

Environmental clearance for the new site has already been secured, with several other regulatory approvals still pending; management expects actual construction to begin within the next three to four months, with the project coming on stream over roughly four to six quarters. The new facility is expected to mirror the company’s existing plant, combining API and speciality chemical manufacturing.

Capacities Running Close to the Limit

Much of the case for fresh capacity comes down to how stretched existing plants already are. Products such as Ibuprofen, Metformin, Clopidogrel and Fenofibrate are running at 85–95% capacity utilization, averaging around 90% for the year, while the company’s ethyl acetate and acetic anhydride units are operating at 98–100% utilisation even after recent capacity enhancements. Ethyl acetate capacity itself was raised from 1,10,000 to 1,20,000 tonnes during the year. 

The newer paracetamol facility, scaled up roughly threefold from 3,600 MT to 10,800 MT installed capacity, is currently running at around 55% utilisation and is expected to climb to 70–75% in FY27, with full utilisation targeted by FY28. Management has pegged the company’s maximum revenue potential from existing capacities, if all lines were run at 100% utilisation, at around ₹3,200–3,300 crore.

Record Quarter Drives the Re-rating

The rally has been underpinned by genuinely strong numbers. Revenue from operations for the March quarter came in at ₹619 crore, up 17.4% year-on-year and the company’s highest-ever quarterly revenue. EBITDA rose nearly 40% year-on-year to ₹94 crore, with margins expanding by 251 basis points to 15.2%. 

Profit after tax jumped 68% year-on-year to ₹53 crore, with PAT margin improving to 8.6%. For the full year, revenue grew 11.5% to ₹2,319 crore, EBITDA rose 29% to ₹290 crore, and PAT increased 36% to ₹138 crore, with the annual EBITDA margin improving to 12.4% from 10.7% a year earlier. 

Management has attributed the improvement mainly to better product mix, higher capacity utilisation and operational efficiency, with only a modest contribution from the uptick in product pricing seen late in the March quarter. The company also spent around ₹160 crore on capex during the year, entirely funded through internal accruals, while operating with a low debt-to-equity ratio of 0.08.

Business Beyond Ibuprofen 

On the chemicals side, capacity additions in Ethyl Acetate and Acetic Anhydride, along with the newly commissioned Triacetin plant, are aimed at deepening backward integration and supply chain resilience. 

In simple terms, these are industrial chemicals the company both sells to outside customers and uses internally as raw materials for its own medicines. Acetic Anhydride, for instance, is a key input for making Paracetamol, with around 50-60% of what the company produces used captively for this purpose and the rest sold in the open market to industries like textiles, paints and pesticides. 

Ethyl Acetate, on the other hand, is entirely sold to outside buyers rather than used in-house, and finds application across pharmaceuticals, flexible packaging, food processing, paints, inks and chemical intermediates  it’s commonly used as a solvent, the same kind of ingredient found in nail polish removers and printing inks. 

Triacetin, the company’s newest addition, is a more versatile chemical with uses spanning the food industry, pharmaceuticals, cosmetics and perfumery, and is also used in cigarette filters; it can additionally serve as a substitute for certain imported chemicals. 

Producing these chemicals in-house instead of buying them from others gives the company more control over costs and reduces the risk of supply disruptions, while the merchant sales of the surplus provide an additional revenue stream beyond what the company needs for its own pharmaceutical manufacturing. 

Conclusion

The sharp rally in IOL Chemicals and Pharmaceuticals reflects more than just market momentum; it’s backed by record earnings, near-full capacity utilization, and growing institutional confidence. 

With a large expansion plan already funded through internal accruals and management staying upbeat on the outlook, the company appears to be building a solid foundation for its next growth phase. Whether the stock’s recent surge has already priced in this potential, or whether there’s more room to run, remains one for investors to watch closely. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Surges 170% in 4 Months as FIIs Increase Stake; Company Unveils ₹1,400 Cr Capex appeared first on Trade Brains.